Medtronic (MDT) said Thursday that it has submitted 510(k) applications to the US Food and Drug Administration (FDA) seeking marketing approval for its MiniMed 780G interoperable pump as an alternate controller enabled insulin pump and SmartGuard algorithm as an interoperable automated glycemic controller.
Medtronic said the submissions are part of a deal announced in August with Abbott Laboratories (ABT) to collaborate on an integrated system based on Abbott's continuous glucose monitoring platform.
Under the agreement, Abbott is supplying Medtronic with a CGM that will work exclusively with Medtronic's smart dosing devices and software.
According to the FDA, a 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as safe and effective as a legally marketed device.
Price: 83.56, Change: -0.19, Percent Change: -0.23
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.